Literature DB >> 3597231

Human variation in the peripheral air-space deposition of inhaled particles.

W D Bennett, G C Smaldone.   

Abstract

Intersubject variability in both peripheral air-space dimensions and breathing pattern [tidal volume (VT) and respiratory frequency (f)] may play a role in determining intersubject variation in the fractional deposition of inhaled particles that primarily deposit in the lung periphery (i.e., distal to conducting airways). In healthy subjects breathing spontaneously at rest, we measured the deposition fraction (DF) of a 2.6-microns monodisperse aerosol by Tyndallometry while simultaneous measurement of VT and f were made. Under these conditions particle deposition occurs primarily in the peripheral air spaces of the lung. As an index of peripheral air-space size, we used measurements of aerosol recovery (RC) as a function of breath-hold time (t) (Gebhart et al. J. Appl. Physiol. 51: 465-476, 1981). In each subject, we measured RC (aerosol expired/aerosol inspired) of a 1.0-micron monodisperse aerosol as a function of breath-hold time for inspiratory capacity breaths of aerosol. The half time (t1/2) (the breath-hold time to reach 50% RC with no breath hold) is proportional to a mean diameter (D) of air spaces filled with aerosol. In the 10 subjects studied, we found a variable DF, range 0.04-0.44 [0.25 +/- 0.12 (SD)]. DF correlated most closely with 1/f, or the period of breathing (r = 0.96, P less than 0.01). There was no significant correlation between DF and t1/2 as an index of peripheral air-space size. In fact there was little deviation in t1/2 in these normal subjects [coefficient of variation (CV) = 0.12].(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3597231     DOI: 10.1152/jappl.1987.62.4.1603

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  14 in total

Review 1.  Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

2.  Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system.

Authors:  Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

Review 3.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

Review 4.  Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.

Authors:  Worth Longest; Benjamin Spence; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-07-09       Impact factor: 2.849

Review 5.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

6.  Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.

Authors:  P Worth Longest; Geng Tian; Navvab Khajeh-Hosseini-Dalasm; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-04-15       Impact factor: 2.849

Review 7.  Aerosols for therapy and diagnosis.

Authors:  M J O'Doherty; R F Miller
Journal:  Eur J Nucl Med       Date:  1993-12

Review 8.  Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.

Authors:  Andrew M Shen; Tamara Minko
Journal:  J Control Release       Date:  2020-07-16       Impact factor: 9.776

9.  Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA.

Authors:  Kurt Nikander; Ivan Prince; Steven Coughlin; Simon Warren; Glyn Taylor
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

10.  Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis.

Authors:  John Denyer; Alex Black; Kurt Nikander; Tony Dyche; Ivan Prince
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.